{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T01:40:54Z","timestamp":1774575654657,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Taichung Veterans General Hospital\/National Yang Ming Chiao Tung University Joint Research Program","award":["TCVGH-YM1130110"],"award-info":[{"award-number":["TCVGH-YM1130110"]}]},{"name":"Show Chwan Memorial Hospital\/National Chung Hsing University Joint Research Program","award":["SRD-112018"],"award-info":[{"award-number":["SRD-112018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10495-025-02223-9","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:20:11Z","timestamp":1768036811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Harnessing pyroptosis to restrain melanoma through aripiprazole"],"prefix":"10.1007","volume":"31","author":[{"given":"Yu-Teng","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Hsiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeng-Jer","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuo-Hung","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Ning","family":"Syu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiau-Shian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Hsun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"2223_CR1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.pbiomolbio.2011.09.011","volume":"107","author":"S Gandini","year":"2011","unstructured":"Gandini S, Autier P, Boniol M (2011) Reviews on sun exposure and artificial light and melanoma. Prog Biophys Mol Biol 107:362\u2013366. https:\/\/doi.org\/10.1016\/j.pbiomolbio.2011.09.011","journal-title":"Prog Biophys Mol Biol"},{"key":"2223_CR2","first-page":"591","volume":"64","author":"GP Guy Jr","year":"2015","unstructured":"Guy GP Jr., Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC, Centers for Disease C, Prevention (2015) Vital signs: melanoma incidence and mortality trends and projections - United States, 1982\u20132030. MMWR Morb Mortal Wkly Rep 64:591\u2013596","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2223_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","volume":"80","author":"SM Swetter","year":"2019","unstructured":"Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, Guild V, Grant-Kels JM, Halpern AC, Johnson TM, Sober AJ, Thompson JA, Wisco OJ, Wyatt S, Hu S, Lamina T (2019) Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 80:208\u2013250. https:\/\/doi.org\/10.1016\/j.jaad.2018.08.055","journal-title":"J Am Acad Dermatol"},{"key":"2223_CR4","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1021\/acschemneuro.7b00087","volume":"8","author":"AB Casey","year":"2017","unstructured":"Casey AB, Canal CE (2017) Classics in chemical neuroscience: Aripiprazole. ACS Chem Neurosci 8:1135\u20131146. https:\/\/doi.org\/10.1021\/acschemneuro.7b00087","journal-title":"ACS Chem Neurosci"},{"key":"2223_CR5","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4088\/jcp.v63n0903","volume":"63","author":"JM Kane","year":"2002","unstructured":"Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of Aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763\u2013771. https:\/\/doi.org\/10.4088\/jcp.v63n0903","journal-title":"J Clin Psychiatry"},{"key":"2223_CR6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/ajhp\/zxab065","volume":"78","author":"MM Rusgis","year":"2021","unstructured":"Rusgis MM, Alabbasi AY, Nelson LA (2021) Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option. Am J Health Syst Pharm 78:862\u2013871. https:\/\/doi.org\/10.1093\/ajhp\/zxab065","journal-title":"Am J Health Syst Pharm"},{"key":"2223_CR7","doi-asserted-by":"publisher","first-page":"e00989","DOI":"10.1002\/prp2.989","volume":"10","author":"HJ Jeong","year":"2022","unstructured":"Jeong HJ, Jung CW, Kim HJ, Park B, Moon Y, Kim JY, Park MJ (2022) Aripiprazole sensitizes head and neck cancer cells to ionizing radiation by enhancing the production of reactive oxygen species. Pharmacol Res Perspect 10:e00989. https:\/\/doi.org\/10.1002\/prp2.989","journal-title":"Pharmacol Res Perspect"},{"key":"2223_CR8","doi-asserted-by":"publisher","first-page":"e0235676","DOI":"10.1371\/journal.pone.0235676","volume":"15","author":"A Badran","year":"2020","unstructured":"Badran A, Tul-Wahab A, Zafar H, Mohammad N, Imad R, Ashfaq Khan M, Baydoun E, Choudhary MI (2020) Antipsychotics drug Aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro. PLoS ONE 15:e0235676. https:\/\/doi.org\/10.1371\/journal.pone.0235676","journal-title":"PLoS ONE"},{"key":"2223_CR9","doi-asserted-by":"publisher","first-page":"e0324257","DOI":"10.1371\/journal.pone.0324257","volume":"20","author":"PH Hou","year":"2025","unstructured":"Hou PH, Chang GR, Chao YT, Chang YT, Hou DH, Huang SS (2025) Aripiprazole use and Lowering the risk of breast cancer in patient with schizophrenia in a National cohort study. PLoS ONE 20:e0324257. https:\/\/doi.org\/10.1371\/journal.pone.0324257","journal-title":"PLoS ONE"},{"key":"2223_CR10","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.2174\/1570159X15666170413115754","volume":"15","author":"EW Tuplin","year":"2017","unstructured":"Tuplin EW, Holahan MR (2017) Aripiprazole, A drug that displays partial agonism and functional selectivity. Curr Neuropharmacol 15:1192\u20131207. https:\/\/doi.org\/10.2174\/1570159X15666170413115754","journal-title":"Curr Neuropharmacol"},{"key":"2223_CR11","doi-asserted-by":"publisher","first-page":"4310","DOI":"10.7150\/thno.71086","volume":"12","author":"Z Rao","year":"2022","unstructured":"Rao Z, Zhu Y, Yang P, Chen Z, Xia Y, Qiao C, Liu W, Deng H, Li J, Ning P, Wang Z (2022) Pyroptosis in inflammatory diseases and cancer. Theranostics 12:4310\u20134329. https:\/\/doi.org\/10.7150\/thno.71086","journal-title":"Theranostics"},{"key":"2223_CR12","doi-asserted-by":"publisher","unstructured":"Zheng Z, Li G (2020) Mechanisms and therapeutic regulation of pyroptosis in inflammatory diseases and cancer. Int J Mol Sci 21. https:\/\/doi.org\/10.3390\/ijms21041456","DOI":"10.3390\/ijms21041456"},{"key":"2223_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/imr.12534","volume":"277","author":"SM Man","year":"2017","unstructured":"Man SM, Karki R, Kanneganti TD (2017) Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol Rev 277:61\u201375. https:\/\/doi.org\/10.1111\/imr.12534","journal-title":"Immunol Rev"},{"key":"2223_CR14","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1038\/s41401-022-00887-6","volume":"43","author":"F Yang","year":"2022","unstructured":"Yang F, Bettadapura SN, Smeltzer MS, Zhu H, Wang S (2022) Pyroptosis and pyroptosis-inducing cancer drugs. Acta Pharmacol Sin 43:2462\u20132473. https:\/\/doi.org\/10.1038\/s41401-022-00887-6","journal-title":"Acta Pharmacol Sin"},{"key":"2223_CR15","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Marquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schoffski P, Carlino MS, Lebbe C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381:1535\u20131546. https:\/\/doi.org\/10.1056\/NEJMoa1910836","journal-title":"N Engl J Med"},{"key":"2223_CR16","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","volume":"35","author":"GV Long","year":"2024","unstructured":"Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance AM, Daud AI, Hamid O, Larkin J, Yao L, Singh R, Lal R, Robert C (2024) Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol 35:1191\u20131199. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2330","journal-title":"Ann Oncol"},{"key":"2223_CR17","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT (2018) Overall survival in patients with BRAF-mutant melanoma receiving Encorafenib plus binimetinib versus Vemurafenib or Encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19:1315\u20131327. https:\/\/doi.org\/10.1016\/S1470-2045(18)30497-2","journal-title":"Lancet Oncol"},{"key":"2223_CR18","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3934\/mbe.2022031","volume":"19","author":"Z Niu","year":"2022","unstructured":"Niu Z, Xu Y, Li Y, Chen Y, Han Y (2022) Construction and validation of a novel pyroptosis-related signature to predict prognosis in patients with cutaneous melanoma. Math Biosci Eng 19:688\u2013706. https:\/\/doi.org\/10.3934\/mbe.2022031","journal-title":"Math Biosci Eng"},{"key":"2223_CR19","doi-asserted-by":"publisher","unstructured":"Zaffaroni N, Beretta GL (2023) The therapeutic potential of pyroptosis in melanoma. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms24021285","DOI":"10.3390\/ijms24021285"},{"key":"2223_CR20","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1158\/2159-8290.CD-19-0672","volume":"10","author":"DA Erkes","year":"2020","unstructured":"Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, Berger AC, Hartsough EJ, Rodeck U, Alnemri ES, Aplin AE (2020) Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discov 10:254\u2013269. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0672","journal-title":"Cancer Discov"},{"key":"2223_CR21","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1158\/0008-5472.CAN-21-3217","volume":"82","author":"W Cai","year":"2022","unstructured":"Cai W, Nguyen MQ, Wilski NA, Purwin TJ, Vernon M, Tiago M, Aplin AE (2022) A genome-wide screen identifies PDPK1 as a target to enhance the efficacy of MEK1\/2 inhibitors in NRAS mutant melanoma. Cancer Res 82:2625\u20132639. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-3217","journal-title":"Cancer Res"},{"key":"2223_CR22","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1080\/10717544.2021.1898703","volume":"28","author":"M Song","year":"2021","unstructured":"Song M, Xia W, Tao Z, Zhu B, Zhang W, Liu C, Chen S (2021) Self-assembled polymeric nanocarrier-mediated co-delivery of Metformin and doxorubicin for melanoma therapy. Drug Deliv 28:594\u2013606. https:\/\/doi.org\/10.1080\/10717544.2021.1898703","journal-title":"Drug Deliv"},{"key":"2223_CR23","doi-asserted-by":"publisher","unstructured":"Mijit M, Caracciolo V, Melillo A, Amicarelli F, Giordano A (2020) Role of p53 in the regulation of cellular senescence. https:\/\/doi.org\/10.3390\/biom10030420. Biomolecules 10","DOI":"10.3390\/biom10030420"},{"key":"2223_CR24","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/febs.16381","volume":"290","author":"M Takasugi","year":"2023","unstructured":"Takasugi M, Yoshida Y, Hara E, Ohtani N (2023) The role of cellular senescence and SASP in tumour microenvironment. FEBS J 290:1348\u20131361. https:\/\/doi.org\/10.1111\/febs.16381","journal-title":"FEBS J"},{"key":"2223_CR25","doi-asserted-by":"publisher","first-page":"607670","DOI":"10.3389\/fcell.2020.607670","volume":"8","author":"E Alvarado-Ortiz","year":"2020","unstructured":"Alvarado-Ortiz E, de la Cruz-Lopez KG, Becerril-Rico J, Sarabia-Sanchez MA, Ortiz-Sanchez E, Garcia-Carranca A (2020) Mutant p53 gain-of-function: role in cancer development, progression, and therapeutic approaches. Front Cell Dev Biol 8:607670. https:\/\/doi.org\/10.3389\/fcell.2020.607670","journal-title":"Front Cell Dev Biol"},{"key":"2223_CR26","doi-asserted-by":"publisher","unstructured":"Castellani G, Buccarelli M, Arasi MB, Rossi S, Pisanu ME, Bellenghi M, Lintas C, Tabolacci C (2023) BRAF mutations in melanoma: biological aspects, therapeutic implications, and Circulating biomarkers. Cancers (Basel) 15. https:\/\/doi.org\/10.3390\/cancers15164026","DOI":"10.3390\/cancers15164026"},{"key":"2223_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrc2694","volume":"9","author":"EF Wagner","year":"2009","unstructured":"Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9:537\u2013549. https:\/\/doi.org\/10.1038\/nrc2694","journal-title":"Nat Rev Cancer"},{"key":"2223_CR28","doi-asserted-by":"publisher","first-page":"e13436","DOI":"10.1111\/imr.13436","volume":"329","author":"A Vervaeke","year":"2025","unstructured":"Vervaeke A, Lamkanfi M (2025) MAP kinase signaling at the crossroads of inflammasome activation. Immunol Rev 329:e13436. https:\/\/doi.org\/10.1111\/imr.13436","journal-title":"Immunol Rev"},{"key":"2223_CR29","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.bbamcr.2006.11.010","volume":"1773","author":"JC Chambard","year":"2007","unstructured":"Chambard JC, Lefloch R, Pouyssegur J, Lenormand P (2007) ERK implication in cell cycle regulation. Biochim Biophys Acta 1773:1299\u20131310. https:\/\/doi.org\/10.1016\/j.bbamcr.2006.11.010","journal-title":"Biochim Biophys Acta"},{"key":"2223_CR30","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1091\/mbc.e06-10-0908","volume":"18","author":"J Villanueva","year":"2007","unstructured":"Villanueva J, Yung Y, Walker JL, Assoian RK (2007) ERK activity and G1 phase progression: identifying dispensable versus essential activities and primary versus secondary targets. Mol Biol Cell 18:1457\u20131463. https:\/\/doi.org\/10.1091\/mbc.e06-10-0908","journal-title":"Mol Biol Cell"},{"key":"2223_CR31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jaci.2022.02.031","volume":"150","author":"Y Li","year":"2022","unstructured":"Li Y, Chang LH, Huang WQ, Bao HW, Li X, Chen XH, Wu HT, Yao ZZ, Huang ZZ, Weinberg SE, Fang DY, Zhang YN, Zhang GH (2022) IL-17A mediates pyroptosis via the ERK pathway and contributes to steroid resistance in CRSwNP. J Allergy Clin Immunol 150:337\u2013351. https:\/\/doi.org\/10.1016\/j.jaci.2022.02.031","journal-title":"J Allergy Clin Immunol"},{"key":"2223_CR32","doi-asserted-by":"publisher","unstructured":"Yang L, Zhang Y, Chai Z, Zhou Y, Li Z, Wei Y (2025) Regulation of pyroptosis by NF-\u03baB signaling. Front Cell Death 3\u20132024. https:\/\/doi.org\/10.3389\/fceld.2024.1503799","DOI":"10.3389\/fceld.2024.1503799"},{"key":"2223_CR33","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.immuni.2014.12.010","volume":"41","author":"R Caruso","year":"2014","unstructured":"Caruso R, Warner N, Inohara N, Nunez G (2014) NOD1 and NOD2: signaling, host defense, and inflammatory disease. Immunity 41:898\u2013908. https:\/\/doi.org\/10.1016\/j.immuni.2014.12.010","journal-title":"Immunity"},{"key":"2223_CR34","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12974-025-03399-2","volume":"22","author":"J Li","year":"2025","unstructured":"Li J, Li S, Sun Q, Li L, Zhang Y, Hua Z (2025) H3K18 lactylation-mediated nucleotide-binding oligomerization domain-2 (NOD2) expression promotes bilirubin-induced pyroptosis of astrocytes. J Neuroinflammation 22:76. https:\/\/doi.org\/10.1186\/s12974-025-03399-2","journal-title":"J Neuroinflammation"},{"key":"2223_CR35","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.4049\/jimmunol.178.4.2380","volume":"178","author":"JH Park","year":"2007","unstructured":"Park JH, Kim YG, McDonald C, Kanneganti TD, Hasegawa M, Body-Malapel M, Inohara N, Nunez G (2007) RICK\/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. J Immunol 178:2380\u20132386. https:\/\/doi.org\/10.4049\/jimmunol.178.4.2380","journal-title":"J Immunol"},{"key":"2223_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.abb.2018.12.022","volume":"670","author":"T Mukherjee","year":"2019","unstructured":"Mukherjee T, Hovingh ES, Foerster EG, Abdel-Nour M, Philpott DJ, Girardin SE (2019) NOD1 and NOD2 in inflammation, immunity and disease. Arch Biochem Biophys 670:69\u201381. https:\/\/doi.org\/10.1016\/j.abb.2018.12.022","journal-title":"Arch Biochem Biophys"},{"key":"2223_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/imr.12902","volume":"297","author":"BC Trindade","year":"2020","unstructured":"Trindade BC, Chen GY (2020) NOD1 and NOD2 in inflammatory and infectious diseases. Immunol Rev 297:139\u2013161. https:\/\/doi.org\/10.1111\/imr.12902","journal-title":"Immunol Rev"},{"key":"2223_CR38","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1126\/science.abc9113","volume":"373","author":"ME Griffin","year":"2021","unstructured":"Griffin ME, Espinosa J, Becker JL, Luo JD, Carroll TS, Jha JK, Fanger GR, Hang HC (2021) Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy. Science 373:1040\u20131046. https:\/\/doi.org\/10.1126\/science.abc9113","journal-title":"Science"},{"key":"2223_CR39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12974-018-1289-z","volume":"15","author":"L Cheng","year":"2018","unstructured":"Cheng L, Chen L, Wei X, Wang Y, Ren Z, Zeng S, Zhang X, Wen H, Gao C, Liu H (2018) NOD2 promotes dopaminergic degeneration regulated by NADPH oxidase 2 in 6-hydroxydopamine model of parkinson\u2019s disease. J Neuroinflammation 15:243. https:\/\/doi.org\/10.1186\/s12974-018-1289-z","journal-title":"J Neuroinflammation"},{"key":"2223_CR40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature11748","volume":"494","author":"W Shao","year":"2013","unstructured":"Shao W, Zhang SZ, Tang M, Zhang XH, Zhou Z, Yin YQ, Zhou QB, Huang YY, Liu YJ, Wawrousek E, Chen T, Li SB, Xu M, Zhou JN, Hu G, Zhou JW (2013) Suppression of neuroinflammation by astrocytic dopamine D2 receptors via alphaB-crystallin. Nature 494:90\u201394. https:\/\/doi.org\/10.1038\/nature11748","journal-title":"Nature"},{"key":"2223_CR41","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1159\/000490218","volume":"47","author":"E Layunta","year":"2018","unstructured":"Layunta E, Latorre E, Forcen R, Grasa L, Castro M, Arias MA, Alcalde AI, Mesonero JE (2018) NOD2 modulates serotonin transporter and interacts with TLR2 and TLR4 in intestinal epithelial cells. Cell Physiol Biochem 47:1217\u20131229. https:\/\/doi.org\/10.1159\/000490218","journal-title":"Cell Physiol Biochem"},{"key":"2223_CR42","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.1113\/JP278640","volume":"597","author":"MM Pusceddu","year":"2019","unstructured":"Pusceddu MM, Barboza M, Keogh CE, Schneider M, Stokes P, Sladek JA, Kim HJD, Torres-Fuentes C, Goldfild LR, Gillis SE, Brust-Mascher I, Rabasa G, Wong KA, Lebrilla C, Byndloss MX, Maisonneuve C, Baumler AJ, Philpott DJ, Ferrero RL, Barrett KE, Reardon C, Gareau MG (2019) Nod-like receptors are critical for gut-brain axis signalling in mice. J Physiol 597:5777\u20135797. https:\/\/doi.org\/10.1113\/JP278640","journal-title":"J Physiol"},{"key":"2223_CR43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-020-2079-1","volume":"579","author":"Q Wang","year":"2020","unstructured":"Wang Q, Wang Y, Ding J, Wang C, Zhou X, Gao W, Huang H, Shao F, Liu Z (2020) A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature 579:421\u2013426. https:\/\/doi.org\/10.1038\/s41586-020-2079-1","journal-title":"Nature"},{"key":"2223_CR44","doi-asserted-by":"publisher","unstructured":"Inkol JM, Westerveld MJ, Verburg SG, Walsh SR, Morrison J, Mossman KL, Worfolk SM, Kallio KL, Phippen NJ, Burchett R, Wan Y, Bramson J, Workenhe ST (2024) Pyroptosis activates conventional type I dendritic cells to mediate the priming of highly functional anticancer T cells. J Immunother Cancer 12. https:\/\/doi.org\/10.1136\/jitc-2023-006781","DOI":"10.1136\/jitc-2023-006781"},{"key":"2223_CR45","doi-asserted-by":"publisher","unstructured":"Liu Y, Fang Y, Chen X, Wang Z, Liang X, Zhang T, Liu M, Zhou N, Lv J, Tang K, Xie J, Gao Y, Cheng F, Zhou Y, Zhang Z, Hu Y, Zhang X, Gao Q, Zhang Y, Huang B (2020) Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol 5. https:\/\/doi.org\/10.1126\/sciimmunol.aax7969","DOI":"10.1126\/sciimmunol.aax7969"},{"key":"2223_CR46","doi-asserted-by":"publisher","first-page":"101781","DOI":"10.1016\/j.smim.2023.101781","volume":"69","author":"SO Vasudevan","year":"2023","unstructured":"Vasudevan SO, Behl B, Rathinam VA (2023) Pyroptosis-induced inflammation and tissue damage. Semin Immunol 69:101781. https:\/\/doi.org\/10.1016\/j.smim.2023.101781","journal-title":"Semin Immunol"},{"key":"2223_CR47","doi-asserted-by":"publisher","first-page":"e0318878","DOI":"10.1371\/journal.pone.0318878","volume":"20","author":"CA Swain","year":"2025","unstructured":"Swain CA, Robbs EJ, Verma L, Brandt H, Seppaenen AL, Cavnar PJ (2025) Characterization of the atypical antipsychotic drug aripiprazole cytotoxicity in the neutrophil model cell line HL-60. PLoS ONE 20:e0318878. https:\/\/doi.org\/10.1371\/journal.pone.0318878","journal-title":"PLoS ONE"},{"key":"2223_CR48","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.18632\/oncotarget.23192","volume":"9","author":"MS Kim","year":"2018","unstructured":"Kim MS, Yoo BC, Yang WS, Han SY, Jeong D, Song JM, Kim KH, Aravinthan A, Kim JH, Kim JH, Kim SC, Cho JY (2018) Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action. Oncotarget 9:5979\u20135992. https:\/\/doi.org\/10.18632\/oncotarget.23192","journal-title":"Oncotarget"},{"key":"2223_CR49","doi-asserted-by":"publisher","first-page":"e70076","DOI":"10.1002\/prp2.70076","volume":"13","author":"LA O\u2019Callaghan","year":"2025","unstructured":"O\u2019Callaghan LA, Blum CB, Powell K, Chess-Williams R, McDermott C (2025) From psychiatry to oncology: exploring the anti-neoplastic mechanisms of aripiprazole and its potential use in cancer treatment. Pharmacol Res Perspect 13:e70076. https:\/\/doi.org\/10.1002\/prp2.70076","journal-title":"Pharmacol Res Perspect"},{"key":"2223_CR50","doi-asserted-by":"publisher","unstructured":"Vlachos N, Lampros M, Voulgaris S, Alexiou GA (2021) Repurposing antipsychotics for cancer treatment. Biomedicines 9. https:\/\/doi.org\/10.3390\/biomedicines9121785","DOI":"10.3390\/biomedicines9121785"},{"key":"2223_CR51","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.7150\/jca.95592","volume":"15","author":"A He","year":"2024","unstructured":"He A, Wu M, Pu Y, Li R, Zhang Y, He J, Xia Y, Ma Y (2024) Fluoxetine as a potential therapeutic agent for inhibiting melanoma brain and lung metastasis: induction of apoptosis, G0\/G1 cell cycle arrest, and disruption of autophagy flux. J Cancer 15:3825\u20133840. https:\/\/doi.org\/10.7150\/jca.95592","journal-title":"J Cancer"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02223-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-025-02223-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02223-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T09:33:29Z","timestamp":1773999209000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-025-02223-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2223"],"URL":"https:\/\/doi.org\/10.1007\/s10495-025-02223-9","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}